Abstract

The present invention relates to a treatment agent for a coronavirus, and, more specifically, to a use for the purpose of treating coronavirus infection by administering a drug or a pharmaceutical composition comprising L-nucleoside represented by chemical formula 1.

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.

IPC Classes  ?

• C07D 239/52 - Two oxygen atoms

Abstract

The present disclosure relates to a method for preparing tolimidone on large scale with maintaining high purity and uniform particle size distribution, and more specifically, a method suitable for preparing tolimidone on industrially large scale by using tetrabutyl ammonium bromide catalyst and recrystallization in ethanol, which can prepare highly pure tolimidone in a time shorter than prior arts while maintaining water content and particle size distribution constantly.

IPC Classes  ?

• C07D 239/52 - Two oxygen atoms
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed are: a compound of chemical formula 1; a pharmaceutically acceptable salt or stereoisomer thereof; and a pharmaceutical composition containing the same. The compound of chemical formula 1 or the pharmaceutically acceptable salt or stereoisomer thereof acts as a multi-target kinase inhibitor, thereby being usable in the prevention or treatment of cancers or immune-related diseases such as rheumatoid arthritis, Sjögren's syndrome, psoriasis, systemic lupus erythematosus, atopy, asthma and multiple sclerosis.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Dentifrices; non-medicated dental rinses; tooth powders; cosmetic soaps; medicated soap; and shampoos Toothbrushes and toothbrush cases